D.E. Shaw & Co
KRYS icon

D.E. Shaw & Co’s Krystal Biotech KRYS Stock Holding History

D.E. Shaw & Co’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.43M Buy
+9,400
New +$2.5M ﹤0.01% 2762

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's KRYS Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Krystal Biotech (KRYS) stake by 53% in Q1 2026, selling an estimated $296K and leaving 996 shares worth $257K. The position accounts for ﹤0.01% of the portfolio, ranked #4119.

D.E. Shaw & Co first reported a position in KRYS in Q2 2021 and has held it in 19 quarters since. The position peaked at $14.6M in Q1 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • D.E. Shaw & Co held 996 shares of Krystal Biotech worth $257K as of Q1 2026.
  • D.E. Shaw & Co sold 1,112 Krystal Biotech shares in Q1 2026, an estimated $296K.
  • Krystal Biotech made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4119 holding.
  • D.E. Shaw & Co first reported a position in Krystal Biotech in Q2 2021 and has held it in 19 quarters since.
  • D.E. Shaw & Co's Krystal Biotech position peaked at $14.6M in Q1 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.